pic-publications

 

Full Papers

 

  1. van Goenthem N, Schreiber R, Newman-Tancredi A, Varney M, Prickaerts, J (2014) Divergent effects of the novel “biased”, 5-HT1A receptor agonists F15599 and F13714 in a novel cognition task: object pattern separation, submitted
  2. Schreiber R, Newman-Tancredi A (2014). Improving cognitive impairment associated with schizophrenia with antipsychotics that elicit adult neurogenesis through 5-HT1A receptor activation. Neurobiol Learning & Memory, in press
    2013

  3. Abada Y, Nguyen HP, Ellenbroek B, Schreiber R (2013) Reversal learning and associative memory impairments in a BACHD rat model for Huntington disease. PLoS One 8: e71633
  4. Abada Y, Nguyen HP, Schreiber R, Ellenbroek B (2013). Assessment of motor function, sensory motor gating and recognition memory in a novel BACHD transgenic rat model for Huntington’s disease. PLoS One 8: e68584
     
  5. Abada Y, Schreiber R, Ellenbroek B (2013). Motor, emotional and cognitive deficits in adult BAC-HD mice: a model for Huntington’s disease. Behavioral Brain Research 238: 243-51
    2012

     
  6. Prins J, Kenny PJ, Doomernik I, Schreiber R, Olivier B, Korte SM (2012) The triple reuptake inhibitor DOV216,303 induces long-lasting enhancement of brain reward activity as measured by intracranial self-stimulation in rats. European J Pharmacology 693: 51-6
  7. Prickaerts J,  De Vry, J, Boere J, Quinton M, Engel S, Melnick L, Schreiber R (2012). Increased BDNF levels in neuronal and astrocytoma cells as  well as in rat hippocampus: triple versus dual reuptake inhibition. J Mol Neurosci 48:167-75
    2011

  8. Christiaan H. Vinkers, Berend Olivier, Taleen Hanania, Wenzhong Min, Rudy Schreiber, Seth C. Hopkins, Una Campbell and Neil Paterson (2011). Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73 in rats trained to discriminate chlordiazepoxide or zolpidem. European Journal of Pharmacology 668: 190-93.
  9. Shao L, Hewitt MC, Wang F, Malcolm SC, Ma J, Campbell JE, Campbell UC, Engel SR, Spicer NA, Hardy LW, Schreiber R, Spear  KL,Varney MA (2011). Discovery of N-methyl-1-(1phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor. Bioorganic and Medicinal Chemistry Letters 21: 1438-1441  
  10. Shao L, Hewitt MC, Wang F, Malcolm SC, Ma J, Campbell JE, Campbell UC, Engel SR, Spicer NA, Hardy LW, Schreiber R, Spear  KL,Varney MA (2011).Discovery of N-methyl-1-(1phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor. Bioorganic and Medicinal Chemistry Letters 21: 1434-1437  
  11. Shao L, Ma J, Wang F, Malcolm SC, Hewitt MC, Campbell UC, Spicer NA Hardy LW, Schreiber R, Spear  KL,Varney MA (2011). Discovery of 1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4- tetrahydroquinolin-4-amine, a dual serotonin and dopamine reuptake inhibitor. Bioorganic and Medicinal Chemistry Letters 21: 520-23
  12. Shao L, Wang F, Malcolm SC, Ma J, Hewitt MC, Campbell UC, Bush LR, Spicer NA, Engel SR, Saraswat LD, Hardy LW, Koch P, Schreiber R, Spear  KL, Varney MA (2011). Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N- methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors. Bioorganic and Medicinal Chemistry Letters 19: 663-76
  13. Prins J, Westphal KGC, Korte-Bouws GA, Quinton MS, Schreiber R, Olivier B, Korte SM (2011). The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: A microdialyis study in olfactory bulbectomized rats. Pharmacology, Biochemistry and Behaviour 97:444-52.
    2010

     
  14. Blokland A, Schreiber R, Prickaerts J (2010) Improving memory: a role for phosphodiesterases. Frontiers in Medicinal Chemistry 5: 58-80
  15. McArthur RA, Gray J, Schreiber R (2010) Cognitive effects of muscarinic M1 agonists in nonhuman primates. Current Opinion in Investigational Drugs 11: 740-60.
  16. Feifel D, Pang Z, Shilling PD, Melendez G, Schreiber R,  Button D (2010) Effects of Neurotensin-2 Receptor Deletion on Baseline and Haloperidol-Enhanced Sensorimotor Gating. Behavioral Brain Research 212:174-8.
  17. Feifel D, Pang Z, Shilling PD, Melendez G, Schreiber R, Button D. (2010) Sensorimotor gating in neurotensin-1 receptor null mice, Neuropharmacology, 58: 173-8.
  18. Prins J, Denys DA, Westphal KGC, Korte-Bouws GA, Quinton MS, Schreiber R, Groenink L, Olivier B, Korte SM (2010) The putative antidepressant DOV216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats. Eur J Pharmacol 633:55-61.
    2009

     
  19. Secchi RL, Sung E, Hedley LR, Button D, Schreiber R (2009) The neurotensin agonist NT69L Improves sensorimotor gating deficits induced by the NMDA antagonist dizocilpine, but not dopaminergic agonists, in rats. Behavioral Brain Res, 202: 192-7.
  20. Mechanic JA, Sutton JE, Pang Z, Button DC, Schreiber R (2009) Pharmacological responsiveness of ntr1 wt and -/- mice: involvement in hypothermic, antinociceptive, and antipsychotic effects of neurotensin analogs. Eur Neuropsychopharmacology, 19: 466-75
  21. Schröder UH, Müller T, Schreiber R, Stolle A, Zuschratter W, Balschun D, Jork R, Reymann KG (2009). The potent non-competitive mGlu1 receptor antagonist BAY 36-7620 differentiallly affects synaptic plasticity in area cornu ammonis 1 of rat hippocampal slices and impairs acquisition in the water maze task in mice. Neuroscience 157: 385-95
    2008

     
  22. Breuer ME, Chan JSW, Oosting R, Groenink L, Korte SM, Campbell U, Schreiber R, Hanania T, Snoeren EMS, Waldinger M, Olivier B (2008). The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects. Eur Neuropsychopharmacology, 18: 908-16.
  23. Animal models of obsessive-compulsive disorders: from bench to bedside via endophenotypes and biomarkers. Joel D, Stein DJ, Schreiber R (2008) In: Animal and Translational Models for Drug Discovery. Volume 1: Psychiatric Disorders. RA McArthur and F. Borsini (Eds). Elsevier, p. 133-154
    2007

     
  24. Schreiber R, Vivian J, Szczepanski K, Secchi R, Zuzow M, Hedley L, Martin JR, Moreau JL, Sik A, Blokland A (2007) Behavioral characterization of the novel 5-HT6 receptor antagonist RO4368554 in rat models for cognition and prepulse inhibition of the acoustic startle response. Eur Neuropsychopharmacology, 17: 277-88
    2006

     
  25. Blokland A, Schreiber R, Prickaerts J (2006) Improving memory: a role for phophodiesterases. Curr Pharm Des 12: 2511-23.


     

  26. Schreiber R, Sleight A, Woolley M (2006) 5-HT6 receptors as targets for the treatment of cognitive deficits in schizophrenia. In: “The 5-HT Receptors: From Molecular Pharmacology to Human Therapeutics”, Ed. B. L. Roth. The Humana Press Inc., Totowa, New Jersey, USA, 495-515.
    2005

     
  27. Lieben CKJ, Blokland A, Sik A, Sung E, van Nieuwenhuizen P, Schreiber R (2005) Cognition-enhancing effects of the selective 5-HT6 receptor antagonist Ro4368554 in cholinergic and serotonergic models of memory deficiency in the rat. Neuropsychopharmacology 30: 2169-79
    2004

     
  28. Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de vente J, Prickaerts J, Blokland A, Koenig G (2004) Inhibition of phophodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 47: 1081-1092.
  29. De Vry J, Schreiber R, Melon C, Dalmus M, Jentzsch KR (2004). 5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat. Eur Neuropharmacol 14:487-495.
  30. De Vry J, Schreiber R, Eckel G, Jentsch KR (2004) Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR141716A. Eur J Pharmacol 483: 55-63
  31. Van Kampen M, Selbach K, Schneider R, Schiegel E, Boess F, Schreiber R (2004) AR-R 17779 improves social recognition in rats by activation of nicotinic a7 receptors. Psychopharmacology 172: 375 - 383.
    2003

     
  32. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R (2003) Insight into the function of group I and group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol. 14:257-77.
    2002

  33. Schreiber R, De Vry J (2002)  Role of 5-HT2C receptors in the hypophagic effect of m-CPP, ORG 37684 and CP-94,253 in the rat. Progress in Neuro-Psychopharmacology & Biological Psychiatry 26:441- 449.
  34. Schreiber R, Dalmus M, De Vry J (2002) Effects of a4b2- and a7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology 159: 248 - 257.
    2000

     
  35. De Vry J, Eckel E, Kuhl E, Schreiber R (2000) Effects of serotonin 5-HT1 and 5-HT2 receptor agonists in a conditioned taste aversion paradigm in the rat. Pharmacology, Biochemistry and Behaviour 66: 797-802.
  36. De Vry J, Schreiber R (2000) Effects of selected serotonin 5-HT1 and 5-HT2 receptor agonists on feeding behavior : possible mechanisms of action. Neurosci Biobehav Rev 24: 341-353
  37. Maurel S, Schreiber R, De Vry J (2000) Palatable sweet fluids do not affect alcohol intake and its reduction by serotonergic compounds in alcohol-preferring cAA rats. Eur. Neuropsychopharmacol. 10: 351-353
  38. Schreiber R, Freund WD (2000) Glutamate transport is downregulated in the cerebral cortex of alcohol-preferring rats. Med. Sci. Monit. 6: 649-652.
  39. Schreiber R, Lowe D, Voerste A, De Vry J (2000) LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine. Eur J Pharmacol 388: R3-R4
  40. Schreiber R, Selbach K, Asmussen M, Hesse D, De Vry J (2000) Effects of serotonin1/2 receptor agonists on dark-phase food and water intake in rats. Pharmacol Biochem Behav 67: 291-305.
    1999

     
  41. De Vry J, Maurel, S, Schreiber R, de Beun R, Jentzsch, KR (1999) Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism. Eur. J. Neuropsychopharmacology 9 : 461-468.
  42. De Vry J, Schreiber R, De Beun R (1999) Discriminative and affective stimulus effects of dihydropyridine calcium channel modulators : relationship to antialcohol effects. Pharmacol Biochem Beh 64 : 203-211
  43. Maurel S, De Vry J, Schreiber R (1999) Comparison of the effects of the selective serotonin reuptake inhibitors, fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats. Alcohol 17 : 195-201.
  44. Maurel S, De Vry J, Schreiber R (1999) 5-HT receptor ligands differentially affect the reinforcing stimulus effects of ethanol in an oral operant self-administration paradigm in the rat. Eur J Pharmacol. 370 : 217-223.
  45. Maurel S, De Vry J, de Beun R, Schreiber R (1999) 5-HT2A and 5-HT2C receptors are differentially involved in alcohol preference and consummatory behavior in cAA rats. Pharmacol Biochem Behav. 62 : 89-96.
  46. Millan MJ, Brocco M, Gobert A, Schreiber R, Dekeyne A (1999) S 16924 ((R-2-{1-[2-(2,3-dihydro-benzo[1,4] dioin-5-yloxy)-ethyl-pyrrolidin-3yl}-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties : III. anxiolytic actions in comparison with clozapine and haloperidol. J. Pharmacol. Exp. Ther. 288 : 1002-1014.
  47. Schreiber R, De Vry J (1999) Effects of the 5-HT1A receptor agonist ipsapirone on operant self-administration of ethanol in the rat. Eur. Neuropharmacol 10: 37-42.
  48. West MW, Biggs TAG, Schreiber R, De Vry J, Myers RD (1999) Calcium channel agonist (-)-BAY k8644 suppresses free and limited access intake of alcohol in genetic drinking rats. Psychopharmacology 142 : 261-269.
    1998

     
  49. Maurel S, Schreiber R, De Vry J (1998) Role of 5-HT1B, 5-HT2A and 5-HT2C receptors in the generalization of 5-HT receptor agonists to the ethanol cue in the rat. Beh Pharmacol. 9 : 337-343
  50. Maurel S, Schreiber R De Vry J (1998) Lack of potentiation of the anti-alcohol effects of fluoxetine by pindolol in alcohol-preferring cAA rats. Prog Neuro-Psychopharmacol & Biol Psychiat. 22: 1361-1378.
  51. Millan MJ, Schreiber R, Dekeyne A, Rivet JM, Bervoets K, Mavridis M, Sebban C, Maurel-Remy S, Newman-Tancredi A, Spedding M, Muller O, Lavielle G, Brocco M (1998) S 16924 ((R-2-{1-[2-(2,3-dihydro-benzo[1,4] dioin-5-yloxy)-ethyl-pyrrolidin-3yl}-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties : II. functional profile in comparison to clozapine and haloperidol. J. Pharmacol. Exp. Ther. 286 : 1356-1373.
  52. Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, Nicolas JP, Peglion JL, (1998) S 18126 ({2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl}), a potent, selective and competitive antagonist at dopamine D4 receptors : an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridone) and raclopride. J. Pharmacol. Exp. Ther. 287: 167-186.
  53. Putzke J, De Beun R, Schreiber R, De Vry, J, Tölle, TR, Zieglgänsberger W, Spanangel R (1998) Long-term alcohol self-administration and alcohol withdrawal differentially modulate microtubule-associated protein 2 (MAP2) gene expression in the rat brain. Mol. Brain Res. 62: 196-205.
  54. Schreiber R, Melon C, De Vry J (1998) The role of the 5-HT subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test. Psychopharmacology 135: 383-391.
    1997

     
  55. De Vry J, Schreiber R (1997) The chronic mild stress depression model: future development from a drug discovery perspective. Psychopharmacology 134: 349-350.
  56. Maurel Remy S, Schreiber R, De Vry J (1997) Substitution of the selective serotonin reuptake inhibitors fluoxetine and paroxetine for the discriminative stimulus effects of ethanol in rats. Psychopharmacology 130: 404-406.
  57. Millan MJ, Hjorth S, Samanin R, Schreiber R, Jaffard R, De Ladonchamps B, Veiga S, Goument B, Peglion JL, Spedding M, Brocco M (1997) S 15535, a novel benzodioxopiperazine ligand of serotonin(5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties. J Pharmacol Exp Ther 282: 148-161.
    1996

     
  58. De Beun R, Schneider R, Klein A, Lohmann A, Schreiber R, De Vry J (1996) The calcium channel agonist BAY k 8644 reduces ethanol intake and preference in alcohol-preferring AA rats. Psychopharmacology 127: 302 - 310.
  59. De Beun R, Lohmann A, Kuhl E, Dalmus M, Schreiber R, De Vry J (1996) Stimulus properties of the L-type calcium channel agonist BAY k 8644 in rats. Behavioural Pharmacology 7: 346 - 354.
  60. Maurel Remy S, Schreiber R, Dalmus M, De Vry J (1996) Somatodendritic 5-HT1A receptors are critically involved in the anxiolytic effects of 8-OH-DPAT. Psychopharmacology 125: 89 - 91.
    1995

     
  61. Jolas T, Schreiber R, Laporte AM, Chastanet M, De Vry J, Glaser T, Adrien J, Hamon M (1995) Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat? J Pharmacol & Exp Ther: 272: 920 - 929.


     

  62. Schreiber R, Brocco M, Audinot V, Lefebvre, B, Millan, M (1995) Involvement of 5-HT1A receptors in the anxiolytic action of S 14671 in the pigeon conflict test. Pharmacol Biochem & Behav 51: 211 - 215.
  63. Schreiber R, Brocco M, Audinot V, Gobert, A, Veiga, S, Millan, M (1995) DOI-induced head-twitches in the rat are mediated by 5-HT2A receptors: modulation by novel 5-HT2A/2C antagonists,  D1 antagonists and 5-HT1A antagonists. J Pharmacol & Exp Ther 273: 101 - 112.
  64. Schreiber R, Brocco M, Lefebvre de Ladonchamps B, Monneyron S, Millan, M (1995) A drug discrimination analysis of novel 5-HT1A receptor ligands in the rat using the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tertalin. J Pharmacol & Exp Ther 275: 822 - 831.
    1994

     
  65. Schreiber R, Brocco M, Gobert, A, Veiga, S, Millan, M (1994) The potent activity of the 5-HT1A receptor agonists, S 14506 and S 14671, in the rat forced swimming test is blocked by novel 5-HT1A receptor antagonists. Eur J Pharmacol 271: 537 - 541.
  66. Schreiber R, Brocco M, Millan M (1994) Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone. Eur J Pharmacol 264: 99 - 102.
    1993

     
  67. De Vry J, Schreiber R (1993) Comparison of acute and repeated treatment with the 5-HT1A receptor ligands 8-OH-DPAT and ipsapirone in animal models of anxiety and depression. Drug Dev Res 30: 91-103.
  68. De Vry J, Benz U, Schreiber R, Traber J (1993) Shock-induced ultrasonic vocalization in young adult rats: an animal model for testing putative anti-anxiety drugs. Eur J Pharmacol 249: 331-339.
  69. Schreiber R, De Vry J (1993) 5-HT1A receptor ligands in animal models of anxiety, impulsivity and depression: multiple mechanisms of action. Prog Neuro-Psychopharmacol Biol Psychiatry 17: 87-104.
  70. Schreiber R, De Vry J (1993) Studies on the neuronal circuits involved in the discriminative stimulus effects of 5-HT1A receptor agonists in the rat. J Pharmacol & Exp Ther 265: 572-579.
  71. Schreiber R, De Vry J (1993) Neuronal circuits involved in the anxiolytic effects of the 5-HT1A receptor agonists 8-OH-DPAT, ipsapirone and buspirone in the rat. Eur J Pharmacol 249: 341-351.
  72. Schreiber R, De Vry J (1993) Neuroanatomical basis for the antidepressant-like effects of the 5-HT1A receptor agonists 8-OH-DPAT and ipsapirone in the rat forced swimming test. Behavioural Pharmacology 4: 625-636.
  73. Schreiber R, Opitz K, De Vry J, Glaser T (1993) Ipsapirone and 8-OH-DPAT reduce ethanol preference in rats: involvement of presynaptic 5-HT1A receptors. Psychopharmacology 112: 100-110.
  74. Sommermeyer H, Schreiber R, Greuel J, De Vry J, Glaser T (1993) Anxiolytic effects of the 5-HT1A receptor agonist ipsapirone in the rat: neurobiological correlates. Eur J Pharmacol 240: 29-37.
    1992

     
  75. De Vry J,Schreiber R, Glaser T, Traber J (1992) Behavioural pharmacology of 5-HT1A  agonists: animal models of anxiety and depression. In: Stahl SM et al (eds.): Serotonin1A Receptors in Depression and Anxiety, Raven Press, New York: 55-81.
    1991

  76. De Vry J, Glaser T, Schuurman T, Schreiber R, Traber J (1991) 5-HT1A receptors in anxiety. In: Briley M, File SE (eds.): New Con­cepts in Anxiety. Mac Millan Press, London: 94- 129.
  77. Glaser T, Greuel JM, Horvath E, Schreiber R, De Vry J (1991) Differentiation of 8-OH-DPAT and ipsapirone in animal models of 5-HT1A receptor function. In: Fozard J, Saxena P (eds.): Serotonin: Molecular Biology, Receptors and Functional Effects. Birkhauser-Verlag, Basel/Switzerland: 460-470.
  78. Glaser T, De Vry J, Dompert WU, Greuel JM, Schreiber R, Traber J (1991) Seroto­nin und Angst: die Rolle von Serotonin1A Rezeptoren am Beispiel von Ipsapiron. In: Beckmann H, Osterheider M (eds.): Die Rolle von Neurotransmittern bei psychischen Erkrankungen (Tropon-Symposium), Springer-Verlag: 93-105.
    1990

     
  79. Schreiber R, Belinfante-Van Gelder ME (1990) Serotonin, slaap en depressie. Psychologie 8: 36 - 37.

 


 

Abstracts

  1. Divergent effects of the novel “biased”, 5-HT1A receptor agonists F15599 and F13714 in a novel cognition task: object pattern separation. Schreiber R, van Goenthem N, Newman-Tancredi A, Varney M, Prickaerts, J (2013) Soc. NeuroSci. Abs. 865.18
  2. Motor, cognitive and emotional investigation in a novel rat model of Huntington’s disease. Yah-se ABADA, Phuc NGUYEN, Rudy SCHREIBER, Bart ELLENBROEK (2012) Journal of Neurology Neurosurgery & Psychiatry, volume 83 suppl 1, p. A17-A18
  3. Assessing drug action beyond target engagement using pharmacological MRI .  J. Upadhyay J, Nutile L, Schwarz AJ, Wallin D,  Anderson J, Pendse G, Bishop J, George E, Baumgartner R, Coimbra A, Robertson B, Schreiber R, Iyengar S, Bleakman D, Hargreaves R, Becerra L, Borsook D. (2009) Soc. Neurosci. Abs. 34: 358.10
  4. Pharmacological characteristics of SEP230864: Application towards the treatment of neuropsychiatric diseases. Lew R, Schreiber R, Bowen C, Engel S, Hardy L, Quinton M, Shao L, Spicer N, Campbell U (2009). Soc. Neurosci. Abs. 34: 549.7.
  5. Pharmacological characterization of the triple monoamine transporter uptake inhibitor SEP-225289. Schreiber R, Lew R, Hardy L, Cremers T, Fang QK, Campbell U. (2009) Soc. Neurosci. Abs. 34: 549.8
  6. The novel triple reuptake inhibitor SEP-0228425 exhibits antidepressant, anxiolytic and analgesic efficacy in rodent behavioral tests. Campbell U, Engel S, Hardy L, Hewitt M, Olivier B, Shao L, Spicer N, Schreiber R, (2009). Soc. Neurosci. Abs. 34: 549.9
  7. Vivian JA, Mechanic JA, Schreiber R (2004) Alpha-7 nicotinic receptor agonists improve memory in adult rats. Soc. Neurosci. Abst. 30
  8. Lieben CKJ, Sung E, Sik A, Blokland A, Schreiber R (2003) Cognitive effects of the acetylcholinesterase inhibitor metrifonate and the 5-HT6 antagonist Ro4368554 in several rat models of memory deficiency in the object recognition test. Behav Pharmacol 14 (Suppl 1): S31.
  9. Mechanic JA, Sutton JE, Pang Z, Button DC, Schreiber R (2003) Pharmacological responsiveness of ntr1 wt and -/- mice: involvement in hypothermic, antinociceptive, and antipsychotic effects of neurotensin analogs. Soc. Neurosci. Abst. 29: 539-13
  10. Schreiber R and De Vry J (2003) behavioural mechanisms underlying the hypophagic effect of the cannabinoid CB1 receptor antagonist SR 141716A in rats. Behav Pharmacol 14 (Suppl 1): S48
  11. Thompson J, Vivian J, Sadri A, Szczepanski K, Conroy K, Stock H, Schreiber R, Lew R (2003) Inhibition of the γ-aminobutyric acid transporter (GAT) fails to produce anxiolytic- and antidepressant-like activity in rodents. Soc. Neurosci. Abst. 29: 936-18
  12. Schroeder UH, Schreiber R, Stolle A, Mueller T, Jork R, Reymann KG (2002). A novel mGluR1 antagonist differentially affects synaptic plasticity in CA1 of rat hippocampal slices and impairs acquisition in the water maze task. Neuropharmacol 43: 307
  13. Szczepanski K, Vivian JA, Dorsch K, Blokland A, Hedley L, Lieben CKJ, Martin JR, Moreau JL, Secchi R, Sik A, Sung E, Schreiber R (2002) Procognitive effects of the 5-HT6 receptor antagonist RO4368554 in rats. Soc. Neurosci. Abst. 28: 290-20
  14. Baumann K, Popp A, König G and Schreiber R, (2001) Behavioral deficits in mutant APP knock-in x PS1 mice coincide with an increase in Aß42 levels. Proceedings of the 5th Conference on Progress in Alzheimer’s Disease and Parkinson’s Disease, Kyoto, 31.3 – 5.4.2001: 69.
  15. Schreiber R, De Vry J (2001) Neuroleptics differentially reverse effects of phencyclidine and DOI in drug discrimination and prepulse inhibition models in the rat. Beh. Pharmacol. 12 (Suppl. 1): S92
  16. Schreiber R, Dalmus M, De Vry J (2001) Effects of a4b2- and a7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Beh. Pharmacol. 12 (Suppl. 1): S92
  17. Chapman A, Nana K, Meldrum BS, Schreiber R, De Vry J, Müller, T. (2000) Anticonvulsant activity in mice of BAY 36-7620, a novel, selective mGluR1 antagonist. Soc Neurosci Abst 26: 618.11
  18. Müller T, De Vry J, Schreiber R, Horvath E, Mauler F, Stolle A, Lowe D (2000) BAY 36-7620, a selective metabotropic glutamate receptor1 (mGluR1) antagonist with anticonvulsant and neuroprotective properties. Soc Neurosci Abst 26: 618.10
  19. Schreiber R, De Vry J (2000) Role of a4b2- and a7-nicotine acetylcholine receptors (nAChRs) in the control of prepulse inhibition of the acoustic startle response. Soc Neurosci Abst 26: 16.1.
  20. Schreiber R, De Vry J (2000) Role of 5-HT2C and 5-HT1B receptors in the control of feeding behaviour in the rat. Int J Neuropsychopharmacol 3 (Suppl 1): S369
  21. De Vry J, Jentzsch KR, Schreiber R (1999) : Effects of selective 5-HT1/2 receptor agonists on operant food intake in rats. Beh. Pharmacol. 10 (Suppl. 1) : S26.
  22. De Vry J, Eckel G, Kuhl E, Schreiber R (1999) : Effects of selective 5-HT1/2 receptor agonists in a conditioned taste aversion paradigm in rats : relationship to hypophagic properties. Beh. Pharmacol. 10 (Suppl. 1) : S25-S26
  23. De Vry J, Maurel S, Schreiber R (1999) Palatable sweet fluids do not affect alcohol intake and alcohol intake-reducing effect of serotonergic compounds in alcohol-preferring cAA rats. Beh. Pharmacol. 10 (Suppl. 1) : S26-S27
  24. Schreiber R, De Vry J (1999) : Effects of 5-HT1/2 receptor agonists on dark-phase ingestive behavior in rats. Beh. Pharmacol. 10 (Suppl. 1) : S82.
  25. Schreiber R, De Vry J (1999) : Effects of subchronic treatment with fenfluramine and the 5-HT2C receptor agonists m-CPP and ORG 37684 on ingestive behavior and body weight gain in the rat. Beh. Pharmacol. 10 (Suppl. 1) : S81.
  26. Schreiber R, Dalmus M, Lowe D, De Vry J (1999) : No reversal of the phencyclidine-induced disruption of sensorimotor gating by the metabotropic glutamate receptor (mGluR) group II agonist, LY354740, in the rat. Beh. Pharmacol. 10 (Suppl. 1) : S81
  27. Schreiber R, De Vry J (1999) : Evaluation of the effects of the 5-HT1A receptor agonist ipsapirone on operant self-administration of ethanol in the rat. Beh. Pharmacol. 10 (Suppl. 1) : S82
  28. Dekeyne A, Audinot V, Schreiber R, Monneyron S, Millan MJ (1998): Influence of selective antagonists at dopamine D2, D3 and D4 receptors upon latent inhibition (LI) in the rat. Soc. Neurosci. Abst. 24 : 682.12
  29. De Vry J, Maurel S, Schreiber R, de Beun R, Jentzsch KR (1998) Comparison of the effects of Hypericum extracts, imipramine and fluoxetine in rat models of depression and alcoholism. Eur. Neuropsychopharmacol. 8 : 5162-5163
  30. De Vry J, Maurel S, de Beun R, Schreiber R (1998) Behavioral analysis of the role of serotonin receptors in rat models of alcoholism. Beh Pharmacol 9 (Suppl. 1): S 32.
  31. De Vry J, de Beun R, Schreiber R (1998) Discriminative and affective stimulus effects of calcium channel ligands. Beh Pharmacol. 9 (Suppl. 1): S 107.
  32. Maurel S, Schreiber R, De Vry J (1998) Role of 5-HT receptor subtypes in the discriminative stimulus effects of ethanol in rats. Beh Pharmacol. 9 (Suppl. 1): S 59.
  33. Maurel S, De Vry J, Schreiber R (1998) Effects of selective serotonin reuptake inhibitors in alcohol-preferring cAA rats. Beh Pharmacol. 9 (Suppl. 1): S 59.
  34. Maurel S, Schreiber R, De Vry J (1998) Lack of potentiation of the anti-alcohol effects of fluoxetine by pindolol in alcohol-preferring cAA rats. Beh Pharmacol. 9 (Suppl. 1): S 59.
  35. Maurel S, De Vry J, Schreiber R (1998) Role of 5-HT receptor subtypes in the reinforcing stimulus effects of ethanol in the rat. Beh Pharmacol. 9 (Suppl. 1): S 59.
  36. Schreiber R, Maurel S, De Vry J (1998) Differential effects of serotonergic ligands in an operant ethanol (EtOH) self-administration paradigm and an EtOH drug discrimination paradigm in rats. Soc Neurosci Abst 24: 437.1
  37. De Beun R, Maurel S, Schreiber R, De Vry J (1997) Involvement of 5-HT2A and 5-HT2C receptors in ethanol intake and preference in alcohol-preferring cAA rats. Soc Neurosci Abst 23: 551.8
  38. De Vry J, de Beun R, Manze B, Lohmann A, Schreiber R (1997) Effects of the calcium channel blocker, nimodipine, on the discriminative and reinforcing stimulus properties of alcohol. Eur Neuropsychopharmacol 7 (Suppl 2): S260
  39. Gobert A, Peglion JL, Brocco M, Rivet JM, Schreiber R, Monneyron S, Cistarelli L, Despaux N, Millan MJ (1997) S 18327, a novel phenylimidazolinone antipsychotic agent.II Functional profile in comparison to haloperidol, clozapine, seroquel and olanzapine. Soc Neurosci Abst 23: 747.17
  40. Schreiber R, Lohmann A, Manze B, De Vry J (1997) Effects of the putative anti-craving compounds naltrexone and acamprosate on operant oral self-administration of ethanol in rats. Eur Neuropsychopharmacol 7 (Suppl 2): S260
  41. Schwartz Th, Beckermann B, Bühner K, Horvath E, De Vry J, Opitz W, Scherling D, Schreiber R, Schuhmacher J, Steinke W (1997) Pharmakokinetics of the novel 5-HT1A neuro-protectant BAY x 3702 in the rat. Soc. Neurosci. Abst. 23: 747.7.
  42. Smith JW, Maurel Remy S, Schreiber R, De Vry J (1996) Chronic mild stress causes a decrease in the preference for low ethanol concentrations in male Wistar rats. Eur Neuropsychopharmacol 6: S4-131.
  43. De Beun R, Schreiber R, Smith J, De Vry J (1996) Pharmacotherapy of alcoholism: effects of clinically evaluated compounds in alcohol-preferring AA rats. Behavioural Pharmacology 7 (Suppl. 1): 26.
  44. De Vry J, Jentzsch KR, Melon C, Schreiber R (1996) Profiles and mechanism of action of selective serotonin reuptake inhibitors (SSRIs) in animal models of anxiety and depression. Fortschritte der Neurologie und Psychiatrie (Suppl. 2): 55.
  45. De Vry J, Schneider R, Klein A, Schreiber R, De Beun R (1996) Identification of the 5-HT receptor subtypes involved in ethanol consumption in alcohol-preferring AA rats. Behavioural Pharmacology 7 (Suppl. 1): 28 - 29.
  46. De Vry J, Schreiber R, De Beun R (1996) Stimulus properties of (-)-BAY k 8644, a calcium channel agonist: comparison with the calcium channel antagonist, nimodipine. Behavioural Pharmacology 7 (Suppl. 1): 29.
  47. Maurel Remy S, De Beun R, Schreiber R, De Vry J (1996) A parametric evaluation of the effects of cyanamide on ethanol intake and preference in rats. Eur Neuropsychopharmacol 6: S4-131.
  48. Maurel Remy S, De Beun R, Schreiber R, De Vry J (1996) Ethanol intake-reducing effects of fluoxetine in rats could be due to stimulus substitution. J Psychopharmacol 10 (Suppl): A63.
  49. Overstreet DH, McArthur RA, Lee DYW, Rezvani A, Mason G, Schreiber R, De Vry J, Sinclair D, Tomkins D, Spanagel R, Zieglgänsberger W (1996) Alternatives to naltrexone in animal models. Alcoholism: Clinical and Experimental Research.
  50. Peglion JL, Schreiber R, Monneyron S, Millan MJ (1996) Discriminative stimulus properties of (+)-7-OH-DPAT and (+)-PD 128,907: involvement of dopamine D3/D2 and serotonin (5-HT)1A receptors. Soc. Neurosci. 22: 697.4.
  51. Schreiber R, Melon C, Dalmus M, De Vry J (1996) Characterization of the 5-HT subtypes involved in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat. Behavioural Pharmacology 7 (Suppl. 1): 101.
  52. De Vry J, Schreiber R, De Beun R (1995) Impulse control and serotonergic drugs: commonalities and differences in animal models. Eur. Neuropsychopharmacol 5: 177.
  53. Brocco M, Schreiber R, Audinot V, Millan M (1994) Clozapine and the atypical antipsychotics, risperidone, sertindole and MDL 100,907, block DOI-induced discriminative stimulus effects and head-twitches in male rats. Soc Neurosci Abstr 20: 634.11.
  54. De Vry J, Schreiber R, Sommermeyer H, Greuel J, De Beun R, Glaser T (1994) 5-HT1A receptor agonists: multiple indications and mechanisms of actions? Beh Pharmacol 5: 17.
  55. Millan M, Brocco M, Schreiber R, Rivet JM, Hjorth S, Lacroix P, Samanin R, Jaffard R, File S, Spedding M, Peglion JL (1994) S15535, a novel and selective antagonist at postsynaptic 5-HT1A receptors and agonist at 5-HT1A autoreceptors: actions in models of antidepressive, anxiolytic and promnesic activity. Soc Neurosci Abstr 20: 634.4.
  56. Schreiber R, Brocco M, de Ladonchamps B, Millan M (1994) Discriminative stimulus effects of the serotonin (5-HT1A) receptor antagonists, S 15535, WAY 100,135, SDZ 216,525 and (-) -tertatolol: a comparison to other novel ligands at 5-HT1A receptors. Proceedings of the 3th IUPHAR Satellite Meeting on Serotonin: 92.
  57. Schreiber R, Brocco M, Audinot V, Lefebvre, B, Millan, M (1994) An agonist action at 5-HT1A receptors underlies the anxiolytic actions of 5-HT1A receptor ligands in the pigeon conflict test. Proceedings of the CINP Workshop on Critical Issues in the Treatment of Affective Disorders, Paris: 170.
  58. Schreiber R, Brocco M, Gobert, A, Veiga, S, Millan, M (1994) Involvement of postsynaptic 5-HT1A receptors in the antidepressive actions of S 14506 and S 14671 in the rat forced swimming test. Proceedings of the CINP Workshop on Critical Issues in the Treatment of Affective Disorders, Paris: 114.
  59. Schreiber, R, Monneyron, S, Millan, M (1994) A parametric analysis of the latent inhibition-conditioned emotional response (LI-CER) model of schizophrenia in rats. Soc Neurosci Abst 20
  60. De Vry J, Schreiber R, De Beun R, Opitz K (1993) 5-HT1A receptors and alcohol preference. Eur. Neuropharmacol 3: 218.
  61. Schreiber R, Opitz K, Glaser T, De Vry J (1993) Ipsapirone and 8-OH-DPAT reduce alcohol preference in rats : involvement of pre- and postsynaptic 5-HT1A receptors. Behav. Processes 29 : 113-154.
  62. De Vry J, Schreiber R (1992) Comparison of the anxiolytic and antidepressive effects of diazepam, imipramine and the 5-HT1A receptor ligands ipsapirone and 8-OH-DPAT after repeated administration in the rat. Beh Pharmacol 3 (Suppl 1): 53.
  63. De Vry J, Schreiber R (1992) Discriminative stimulus effects of 5-HT1A receptor ligands in the rat. Beh Pharmacol 3: 526.
  64. De Vry J, Greuel JM, Schreiber R, Glaser T (1992) Characterization of the putative 5-HT1A receptor antagonists BMY 7378 and NAN-190 in animal models reflecting 5-HT1A receptor activity. Beh Pharmacol 3 (Suppl 1): 53.
  65. Glaser T, Schreiber R, Sommermeyer H, De Vry J (1992) Role of serotonin1A receptors in models of anxiety and depression after acute and subchronic treatment. Polish J pharmacology & Pharmacy 44 (Suppl): 27.
  66. Schreiber R, Sommermeyer H, Greuel J, Glaser T, De Vry J (1992) Involvement of pre- and postsynaptic 5-HT1A receptors in the anxiolytic, antidepressive and discriminative effects of 8-OH-DPAT and ipsapirone. J Psychopharmacology (Suppl): A52.
  67. De Vry J, Schreiber R, Glaser T (1991) Behavioural pharmacology of the 5-HT1A receptor ligands ipsapirone and 8-OH-DPAT in rats after repeated administration. Soc Neurosci Abstr 17: 116.4.
  68. Schreiber R, Opitz K, De Vry J, Glaser T (1991) Neuroanatomical basis of the alcohol-preference-reducing effects of the 5-HT1A receptor ligands 8-OH-DPAT and ipsapirone. Proceedings of Serotonin 1991: 5-Hydroxy-tryptamine-CNS receptors and brain function, Birmingham: P102.
  69. Sommermeyer H, Schreiber R, Greuel J, De Vry J, Glaser T (1991) Electrophysiologi­cal and  biochemical correlates of the anxiolytic activity of ipsapirone in the rat. In: Rollema  H, Westerink B, Drijfhout WJ (eds.): Monitoring Molecules in Neuroscience, Proceedings of the 5th International Conference on in vivo Methods: 404-406
  70. De Vry J, Schreiber R (1990) Neuroanatomical correlate of the discriminative stimulus effects of the 5-HT1A receptor ligands 8-OH-DPAT and ipsapirone in the rat. Psychopharmacology 101 (suppl.): S67.
  71. Schreiber R, De Vry J (1990) Neuroanatomical correlate of the anxiolytic effects of the 5-HT1A receptor ligands 8-OH-DPAT, ipsapirone and buspirone in the rat. Psychopharmacology 101 (suppl.): S52.
  72. Schreiber R, De Vry J (1990) Neuroanatomical correlate of the antidepressant-like effects of ipsapirone and 8-OH-DPAT in the rat forced swimming test. Psychopharma­cology 101 (suppl): S52.
  73. Schreiber R, De Vry J (1990) Involvement of pre- and postsynaptic mechanisms in the antidepressive effects of the 5-HT1A receptor ligands 8-OH-DPAT, ipsapirone and buspirone in the rat forced swimming test. Proceedings of the 12th Low Countries  Meeting, Cologne: 79.
  74. Schreiber R, De Vry J (1990) Involvement of pre- and postsynaptic mechanisms in the anxiolytic effects of the 5-HT1A receptor ligands 8-OH-DPAT, ipsapirone and buspirone in the rat. Proceedings of the 12th Low Countries Meeting, Cologne: 32
  75. Spencer DG Jr, De Vry J, Schreiber R, Traber J (1990) Pharmacology of 5-HT1A agonists. Clin Neuropharmacol 13 (suppl2): 93-94.
  76. De Vry J, Horvath E, Schreiber R, Traber J (1989) Animal models of 5-HT1A receptor function. Naunyn-Schmiedeberg's Arch Phar­macol 340: R26.
  77. Schreiber R, De Vry J (1989) Involvement of the dorsal raphe nucleus in the discrimi­native  stimulus properties of the 5-HT1A receptor agonist 8-OH-DPAT. Soc Neurosci Abstr  15 (1): 222.

 

Today2018-07-21
design: www.biird.nl